Mirxes secures US$50 Million in Series D funding and files listing application with The Stock Exchange of Hong Kong Limited

Mirxes will jonin in 2024 CACLP in Chongqing on March.

Mirxes Holding Company Limited, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today the successful completion of its Series D funding round, securing a total of US$50 million. The funding will play a pivotal role in accelerating Mirxes’s delivery of cutting-edge cancer early detection blood tests and preventive healthcare solutions in major markets. This Series D funding is anchored by existing and new investors including Beijing Fupu which the Management Committee of Zhejiang Anji Economic Development Zone indirectly owned a majority stake, EDB Investments Pte Ltd, wholly owned by the Singapore Economic Development Board, Agency for Science, Technology and Research, Singapore’s lead public sector R&D agency for scientific discovery and technological innovation, Mitsui & Co., Ltd., a company which is listed in various stock exchanges in Japan, and NHH Venture Fund.  

Dr. ZHOU Lihan, Co-founder and Chief Executive Officer of Mirxes said, “Amid challenging macro-environment, this new investment further validates the clinical and socio-economic impact of our proprietary miRNA technology platform, and continues to position Mirxes as a frontrunner in the global fight against cancer through early detection. We are honored by the tremendous support and confidence from our existing and new investors. This fresh funding will fuel our ambitious growth plans and enable us to continue making a significant impact in the field of multi-cancer early detection.”

The fresh investment will be used primarily to scale adoption and penetration of Mirxes’s flagship stomach cancer blood test, GASTROClearTM in major Asia-Pacific markets including Southeast Asia, People’s Republic of China (PRC) and Japan, and to accelerate the development and commercialization of Mirxes’s maturing clinical pipeline, including a blood-based colorectal cancer screening test and the multi-cancer early detection test under Project CADENCE, an ambitious project to develop a single blood test for early detection of nine high mortality cancers, powered by the company’s first-in-class RNA technology and other complementary biomarker technologies.

In addition to securing the Series D funding, Mirxes is pleased to announce that it has filed the listing application with The Stock Exchange of Hong Kong Limited (HKEX) under Chapter 18A of the Rules Governing the Listing of Securities on HKEX. The company’s commitment to be a leading RNA centric multi-omics technology company that provides accurate, accessible, and actionable diagnostic solutions to address critical unmet clinical needs across the care continuum, has propelled it towards these milestones, which will provide enhanced opportunities for investors and further bolster Mirxes’s global position.

With a strengthened financial position, expanded market presence, and a strategic partnership, Mirxes is well-equipped to drive forward its mission of making early disease detection accessible on a global scale. These developments demonstrate Mirxes’s unwavering commitment to alleviate cancer burden and reduce healthcare costs by leveraging innovative RNA tests that detect diseases earlier, improving health economics and outcomes to foster a healthier future for communities worldwide.

About Mirxes

Mirxex is a Singapore-headquartered RNA technology company that is a pioneer and leader in developing and commercializing accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases.

The story began in early 2000s when its founders pioneered a highly sensitive, specific and robust detection technology for microRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, they decided to bring our technology from lab to clinic.

In 2014, the company spun off from Agency of Science, Technology and Research (A*STAR) to commercialise their technology and develop accurate multi-cancer early detection solutions and make them readily available and accessible to people who need them.

The company believes that the future of healthcare will shift from treating the sick to preventive healthcare. The science and innovation will continue as they are committed to making diagnostic solutions for the early detection of diseases accessible on a global scale.